小檗碱治疗血脂异常的疗效与安全性:随机双盲安慰剂对照试验方案
该研究为随机双盲安慰剂对照试验方案,计划纳入118例血脂异常患者,按1:1随机分组口服小檗碱或安慰剂12周,主要结局为第12周低密度脂蛋白胆固醇下降百分比,并评估其他血脂指标、炎症标志物、血压、体重、肠道菌群等及安全性。
要点
- 小檗碱作为更安全经济的降脂选择,需高质量随机对照试验验证。
- 主要结局为第12周低密度脂蛋白胆固醇下降百分比。
- 次要结局涵盖血脂谱、炎症、血压、体重、肠道菌群及安全性指标。
核心结论
- 该试验旨在为小檗碱治疗血脂异常提供疗效与安全性的高质量证据,并帮助识别可能预测治疗获益的患者特征以优化临床适应症。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,计划纳入118例血脂异常患者,按1:1随机分组,口服小檗碱或安慰剂12周。
关键数值与推荐
- 主要结局为第12周低密度脂蛋白胆固醇下降百分比。
- 其他结局包括其他血脂谱、高敏C反应蛋白、血压、体重、布里斯托粪便量表、中医症状量表、脂肪因子谱及肠道微生物宏基因组变化。
- 安全性评估包括一般体格检查、血尿常规、肝肾功能及不良事件。
临床怎么用
- 试验结果将帮助识别可能从小檗碱治疗中获益的患者特征,并优化其临床适应症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide. The clinical utility of commonly used lipid-lowering drugs such as statins and fibrates is sometimes limited by the occurrence of various adverse reactions. Recently, berberine (BBR) has received increasing attention as a safer and more cost-effective option to manage dyslipidemia. Thus, a high-quality randomized controlled trial to evaluate the efficacy and safety of BBR in the treatment of dyslipidemia is deemed necessary. METHODS/DESIGN: This is a randomized, double-blind, and placebo-controlled clinical trial. A total of 118 patients with dyslipidemia will be enrolled in this study and randomized into two groups at a ratio of 1:1. BBR or placebo will be taken orally for 12 weeks. The primary outcome is the percentage of low-density lipoprotein cholesterol reduction at week 12. Other outcome measures include changes in other lipid profiles, high sensitivity C-reactive protein, blood pressure, body weight, Bristol Stool Chart, traditional Chinese medicine symptom form, adipokine profiles, and metagenomics of intestinal microbiota. Safety assessment includes general physical examination, blood and urine routine test, liver and kidney function test, and adverse events. DISCUSSION: This trial may provide high-quality evidence on the efficacy and safety of BBR for dyslipidemia. Importantly, the findings of this trial will help to identify patient and disease characteristics that may predict favorable outcomes of treatment with BBR and optimize its indication for clinical use. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900021361 . Registered on 17 February 2019.
引用
- Zhao Y, Yang YY, Yang BL, et al. Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial. Trials. 2021. PMID: 33482853. doi:10.1186/s13063-021-05028-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。